HOUSE-BILL 8857: H.R.8857 - Next GEN Act of 2026

Overall Constitutional Implications

The bill's amendments to the Drug Price Negotiation Program could lead to disparities in access to essential medications, particularly affecting marginalized groups. This raises constitutional concerns regarding equal protection and the right to healthcare access, which, while not explicitly guaranteed, is closely tied to the right to life and liberty.

Key Individual Rights Affected

• Right to Health Care Access
• Equal Protection Under the Law

Constitutional Provisions

• Fourteenth Amendment - Due Process Clause
• Fourteenth Amendment - Equal Protection Clause

Potential Constitutional Challenges

The bill may face challenges if it results in higher prices for engineered cyclic peptides, leading to unequal access for low-income individuals, seniors, and those with disabilities. Such disparities could be argued as violations of the Equal Protection Clause.

Summary

HOUSE-BILL 8857 aims to amend the classification of engineered cyclic peptides under the Drug Price Negotiation Program, which could significantly impact individuals' access to these medications. The potential for increased prices raises serious equal protection concerns, particularly for vulnerable populations, indicating a violation of constitutional principles regarding access to healthcare and equal treatment under the law.